The user-friendly key components of the CliniMACS® Plus Instrument offer sophisticated applications for a whole variety of separations. The selected stem cells, monocytes, DCs, NK cells, B cells, and T cell subsets allow research in the field of regenerative medicine, adoptive immunotherapy, and graft engineering.
- Full system control by means of an integrated microcomputer
- Automatized cell separation by a magnetic separation unit including both a movable permanent magnet and a holder for the separation column
- A peristaltic pump to ensure continuity in flow rates throughout the tubing set
- Various pinch valves to support the peristaltic pump in managing the correct flow of buffer and cell suspension
Cells are magnetically labeled in the Cell Preparation Bag using an antigen-specific reagent. Subsequently, the Cell Preparation Bag is connected to the CliniMACS Plus Instrument. Consumer-friendly software facilitates target cell enrichment or depletion as well as final collection in the Cell Collection Bag. The CliniMACS System separates large numbers of cells providing target cells with high purity and excellent yield. A range of tubing sets optimized for different applications is available.
System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.
In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for in vitro
use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations - e.g., for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") - must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.
In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE) or FDA approval.
CliniMACS GMP MicroBeads are for research use and ex vivo
cell processing only.
CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use.